Scholarship Awards $250,000 to Students

Published Online: Monday, December 1, 2003

    McNeil Consumer & Specialty Pharmaceuticals, the makers of Tylenol, awarded $250,000 in grants in its 2003 Tylenol Scholarship program. This year's awards include 10 grants of $10,000 each and 150 of $1000.

    McNeil awards the Tylenol Scholarship in conjunction with local retailers. Recipients are chosen on the basis of leadership in community and school activities, grade point average, and the student?s intended focus on health care?related areas of study.

    "The future of health care is a priority for us, and we are very proud of the accomplishments and dedication of the 2003 Tylenol Scholarship recipients," said Ashley McEvoy, vice president of marketing for McNeil Consumer & Specialty Pharmaceuticals. "It has been our privilege to assist more than 5000 deserving students achieve their academic goals over the past decade."

    Among the largest merit scholarship programs in the United States for all health-related studies, the Tylenol Scholarship is the only scholarship offered to all US residents pursuing health-related fields of study at any post?high school level. "Our commitment to supporting future leaders in health care will continue with the 2004 scholarship program," said McEvoy.

    The 2004 Tylenol Scholarship program will be accepting applications that are postmarked from February 23, 2004, through April 30, 2004. Applications will be available from participating retailers who support the promotion of this program at the community level, and at starting on February 23, 2004. Since its inception in 1991, more than $6 million in scholarship grants has been awarded to more than 5000 students.

Latest Articles
Pharmacies are rated as some of the best places to receive top-notch customer service in America.
Often caused by acid reflux, eosinophilic esophagitis is an emerging inflammatory disease that is generally unresponsive to proton pump inhibitor therapy.
Carlos Aquino, founder and president of PharmaDiversion LLC, discusses timing of inspections from the Drug Enforcement Administration.
The FDA has again rejected AMAG Pharmaceuticals’ application for a single-dose version of hydroxyprogesterone caproate injection (Makena) to reduce the risk of preterm birth for at-risk women.
Latest Issues